

Alana Miller,
National Institute for Health and Clinical Excellence,
Mid City Place,
71 High Holborn,
London,
WC1V 6NA

May 5th 2006

Dear Alana,

Cinacalcet hydrochloride for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy

Please find attached the response from Amgen to the Assessment Report for this appraisal. Please note our request for further development of the PenTAG health economic model and the offer of a collaborative approach.

Could you please confirm you have received this document.

Yours sincerely



Head of HTA